Al-Nimer Marwan, Ratha Rawa, Mahwi Taha
Dr. Marwan Al-Nimer, MD, PhD. Department of Pharmacology and Toxicology, Hawler Medical University, Erbil-Iraq. University of Sulaimani, Sulaimani, Iraq.
Dr. Rawa Ratha. M.Sc. Department of Pharmacology and Toxicology, College of Pharmacy, University of Sulaimani, Sulaimani, Iraq.
Pak J Med Sci. 2019 Sep-Oct;35(5):1370-1375. doi: 10.12669/pjms.35.5.11.
To evaluate the effect of pentoxifylline on the quality of life (QoL) in diabetic foot syndrome (DFS) by using Short Form-36 questionnaire, and in reference to the revised neuropathy disability score (RNDS) and grading of diabetic foot.
This randomized placebo-controlled study was carried in the Department of Pharmacology at University of the Sulaimani through 2018. A total number of 80 T2D patients were recruited from outpatients Department attended the Center of Diabetes and the Shar Teaching Hospital in the University of Sulaimani, Sulaimani-Iraq. Group I (non-DFS, n=40) were subgrouped into Group-IA treated with placebo (n=20), and Group-IB treated with 400 mg pentoxifylline thrice daily for 8 weeks. Group II (DFS, n=40) sub grouped into Group-IIA treated with placebo (n=20), and Group-IIB treated with pentoxifylline. The primary outcome measures including the data of SF-36, RNDS, and grading of diabetic foot.
Pentoxifylline therapy significantly reduced the RNDS, improved the clinical evidence of diabetic foot, improved the QoL particularly the domains that related to emotional problems and physical health. Pentoxifylline offered a better effect in DFS compared with non-DFS patients.
Pentoxifylline treatment improves the quality of life in diabetic foot syndrome and its effect is related to the scoring of revised neuropathy disability and grading of diabetic foot.
通过使用简短健康调查问卷（Short Form-36），并参考修订的神经病变残疾评分（RNDS）和糖尿病足分级，评估己酮可可碱对糖尿病足综合征（DFS）患者生活质量（QoL）的影响。
这项随机安慰剂对照研究于2018年在苏莱曼尼亚大学药理学系进行。从伊拉克苏莱曼尼亚市苏莱曼尼亚大学糖尿病中心和沙尔教学医院门诊招募了80例2型糖尿病患者。第一组（非糖尿病足综合征，n = 40）再分为接受安慰剂治疗的IA组（n = 20）和每日三次服用400 mg己酮可可碱，持续8周的IB组。第二组（糖尿病足综合征，n = 40）再分为接受安慰剂治疗的IIA组（n = 20）和接受己酮可可碱治疗的IIB组。主要观察指标包括简短健康调查问卷、RNDS和糖尿病足分级的数据。
己酮可可碱治疗显著降低了RNDS，改善了糖尿病足的临床症状，改善了生活质量，尤其是与情绪问题和身体健康相关的领域。与非糖尿病足综合征患者相比，己酮可可碱对糖尿病足综合征患者的疗效更好。
己酮可可碱治疗可改善糖尿病足综合征患者的生活质量，其疗效与修订的神经病变残疾评分及糖尿病足分级有关。
